We report three consecutive patients with hypersensitivity syndrome (HSS) due to phenytoin and carbamazepine and successful treatment with gabapentin. HSS is a rare but potentially fatal reaction to multiple drugs including several anticonvulsants. Cross-reactivity among drugs may occur. Immediate withdrawal of the offending drug is the most important step in treatment. Benzodiazepines acutely and, after resolution of the hepatitis, valproic acid have been successfully used for seizure control in patients with HSS. Our cases indicate that gabapentin is also a safe anticonvulsant in HSS.
Introduction
Hypersensitivity syndrome (HSS) was first described as serious systematic adverse reaction to phenytoin 1 . Since then a limited number of additional anticonvulsants and other drugs including sulfonamide and allopurinol have also been associated with this syndrome 2, 3 .
Prompt recognition of HSS and withdrawal of the offending drug is crucial in preventing a possible fatal outcome. The use of a potentially cross-reacting anticonvulsant drug for further seizure control in HSS is not recommended. We present three consecutive cases with successful treatment with gabapentin for seizure control in the presence of HSS due to phenytoin (PHT) and carbamazepine (CBZ).
Case Reports

Case 1
A 43-year-old african-american woman recently diagnosed as having complex partial and secondarily generalized seizures was started on PHT (400 mg/day) ‡ E-mail: hamer@mailer.uni-marburg.de 4 weeks before admission. Four days before admission, the patient developed a pruritic rash. Fever occurred and the patient experienced severe pain in both hip joints.
On admission, the patient had a generalized skin eruption composed of erythematous macules and 2-3 mm follicular-based papules. Tender occipital and submandibular lymphadenopathy and swelling of the lower face was noted. Temperature was 39 • C. Abdominal, cardiac, lung and neurological examinations were normal. Laboratory testing revealed eosinophilia and elevated liver function tests (LFTs; Table 1 ).
Hypersensitivity syndrome to PHT was assumed. Phenytoin was abruptly stopped and CBZ was started with increasing dosages of up to 800 mg/day. In addition, the patient received methylprednisone 180 mg/day iv, diphenhydramine 25 mg four to six times a day and topical corticosteroids. The patient was afebrile for the next 36 hours and felt better. However, on day three, the temperature again rose repeatedly up to 39.5 • C and the rash worsened. Cross-reactivity between PHT and CBZ was suspected. Carbamazepine was discontinued and gabapentin (GBP) was intro- duced. During the following three days, the general clinical symptoms, the cutaneous eruption and the lymphadenopathy improved significantly.
The patient was discharged on GBP 600 mg tid po and prednisone 60 mg/day po with a tapering dose scale. Three days after discharge, the rash returned to a minor extent involving mainly the trunk. No fever or lymphadenopathy occurred. Liver function studies were still abnormal. Treatment was not changed and the rash slowly resolved within the next 5 days. One week later, the patient did not have any clinical symptoms or signs of HSS. The liver function studies became normal within 2 months after admission. The patient was seizure free on GBP monotherapy (1800 mg/day) during a follow-up of 18 months.
Case 2
A 52-year-old caucasian female was started on CBZ 200 mg bid due to complex partial seizures. Six weeks later, the patient was admitted because of a pruritic macular rash involving both arms and legs and to a lesser extent the trunk. Abdominal, cardiac, lung and neurological examinations were normal. No lymphadenopathy was noted. Temperature was 36.5 • C. Laboratory testing revealed eosinophilia and elevated aspartate aminotransferase (Table 1) .
Hypersensitivity syndrome to CBZ was suspected. Carbamazepine was abruptly stopped and PHT was introduced. She also received diphenhydramine 25 mg, four times a day, and topical corticosteroids. The next day, after a total dosage of 750 mg PHT, the rash became more prominent. The temperature rose to 38.0 • C, and perioral swelling was noted. Cross-reactivity between CBZ and PHT was assumed. Phenytoin was discontinued and GBP was introduced. Over the following 4 days, the rash and the facial swelling significantly improved and the patient became afebrile. The facial swelling resolved. The patient was discharged on GBP 1200 mg tid. Laboratory testing became normal within one month. The rash did not return and the patient remained on GBP monotherapy. No seizures occurred during the follow-up of 11 months.
Case 3
A 45-year-old caucasian female was started on PHT 150 mg bid after her first complex partial seizure with secondarily generalization. Six days later, she developed a pruritic rash. Phenytoin was stopped and CBZ was started at a dosage of 100 mg bid. During the following week, the rash worsened. The patient became febrile, felt ill, and experienced myalgias in both legs. On admission, a maculopapular rash was noted involving the trunk and all extremities. Tender generalized lymphadenopathy was present. Laboratory testing revealed eosinophilia and elevated LFTs (Table 1) .
Carbamazepine was abruptly stopped and GBP was introduced. Tropical corticosteroids were applied. Over the next several days, the cutaneous eruptions, lymphadenopathy, and myalgias disappeared. The patient became afebrile. The patient was discharged on GBP 800 mg tid. The eosinophilia resolved and the liver function tests became normal during the next 6 weeks. The patient remained on GBP monotherapy and did not experience any adverse effects. No seizures occurred during a follow-up of 10 months.
Discussion
The cumulative evidence in these three cases indicate that the patients' acute illness was HSS induced by PHT and CBZ, respectively, with possible cross-reaction between the two drugs. Hypersensitivity syndrome has been associated with several aromatic anticonvulsants including PHT, CBZ, phenobarbital (PB), primidone (PRM), felbamate (FBM) and lamotrigine (LTG) [2] [3] [4] . Valproic acid (VPA) is often viewed as safer in respect to cutaneous reactions 5 although there have been oc-casional reports of similar risks of VPA for developing HSS, as compared to aromatic anticonvulsants 6 . To the best of our knowledge, HSS has not yet been described for benzodiazepines, GBP, vigabatrin (VGB), and topiramate (TPM).
The population risk for hypersensitivity syndrome ranges between 1:1000 to 1:10 000 exposures, equally for all associated anticonvulsants 4 . The onset of HSS usually occurs within one week to three months after initiation of drug treatment 4, 7 . Hypersensitivity syndrome is a clinical diagnosis. The hallmarks are fever, rash, tender lymphadenopathy, eosinophilia and hepatitis with abnormal LFTs.
Hypersensitivity syndrome appears to be idiosyncratic 7 . Its exact pathogenesis is unknown. The molecular structure of PHT, CBZ and PB contains an aromatic ring compound which is metabolized to reactive arene oxides. Due to a genetically determined inefficient enzymatic detoxification, these intermediates may accumulate and trigger a systemic auto-immune response 2 . Clinical cross-reactivity between PHT, CBZ, PRM, PB as well as oxcarbazepine (OCBZ) has been reported 4, 8 .
In vitro analyses using lymphocyte toxicity assays suggest up to 80% cross-reactivity between these drugs 2 .
Immediate withdrawal of the drug is the first and most important step in treatment of HSS. In severe cases, systemic corticosteroids and antihistamines may be given 4 . Usually, the rash also responds well to topical steroids, and wet wraps. The majority of the patients completely recover within days or a few weeks 7 . However, the clinical syndrome of hypersensitivity may fluctuate or even relapse with fever and rash for weeks after discontinuation of the offending drug 2, 7 . Note, in patient 1, the rash returned for a brief period of time and resolved without change in treatment.
The use of PHT, PB, PRM, CBZ, OCBZ for further seizure control in HSS is not recommended since potential cross-reactivity can blur or even worsen the clinical course. Felbamate and LTG may also cause HSS and other idiosyncratic reactions and need to be initiated at low dosages and escalated slowly 3 . Therefore, they may not be the anticonvulsant drugs of choice in the presence of HSS. The experience with VGB in Europe is still limited 3 and it is not yet approved in the USA, so that its possible indication in HSS is unclear.
A benzodiazepine can be substituted for acute seizure control 4 . Valproic acid has also successfully been used in the treatment of these patients but probably should not be given during the acute or convalescent phase because of its hepatic metabolism 4, 5 .
The presented cases demonstrate that GBP may be given as anticonvulsant drug in the acute phase of HSS. It can be quickly loaded orally and is not metabolized by the liver, but excreted, unchanged, by the kidney 9 . It has not been associated with HSS or other severe idiosyncratic reactions and has a low potential for other serious adverse effects 9 . Gabapentin is approved as adjunctive drug in the treatment of partial seizures and secondarily generalized tonic-clonic seizures, and has also been shown to be effective as monotherapy 10 . Therefore, GBP seems to be a good alternative drug for seizure control in the presence of HSS to other anticonvulsant drugs.
In conclusion, hypersensitivity syndrome is a rare but serious multiorgan syndrome with a genetic component caused by several anticonvulsant drugs. Immediate withdrawal of the offending drug is the main step to complete recovery. Gabapentin may be the anticonvulsant drug of choice in this situation providing the patient has partial and/or secondarily generalized seizures.
